[Parkinson disease mortality rates in Chile: an under-reported condition].

Chaná-Cuevas P, Díaz V, Juri C.

Rev Med Chil. 2014 Mar;142(3):403-4. doi: 10.4067/S0034-98872014000300021. Spanish. No abstract available.

Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models.

Dorval V, Mandemakers W, Jolivette F, Coudert L, Mazroui R, De Strooper B, Hébert SS.

PLoS One. 2014 Jan 10;9(1):e85510. doi: 10.1371/journal.pone.0085510.

Examining dorsal striatum in cognitive effort using Parkinson's disease and fMRI.

MacDonald AA, Seergobin KN, Tamjeedi R, Owen AM, Provost JS, Monchi O, Ganjavi H, MacDonald PA.

Ann Clin Transl Neurol. 2014 Jun;1(6):390-400. doi: 10.1002/acn3.62.

Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.

Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, Wuolikainen A, Linder J, Moritz T, Blennow K, Antti H, Forsgren L.

J Parkinsons Dis. 2014;4(3):549-60. doi: 10.3233/JPD-140389.

Risk factors and prodromal markers and the development of Parkinson's disease.

Lerche S, Seppi K, Behnke S, Liepelt-Scarfone I, Godau J, Mahlknecht P, Gaenslen A, Brockmann K, Srulijes K, Huber H, Wurster I, Stockner H, Kiechl S, Willeit J, Gasperi A, Fassbender K, Poewe W, Berg

J Neurol. 2014 Jan;261(1):180-7. doi: 10.1007/s00415-013-7171-0.

The effect of deep brain stimulation randomized by site on balance in Parkinson's disease.

St George RJ, Carlson-Kuhta P, Nutt JG, Hogarth P, Burchiel KJ, Horak FB.

Mov Disord. 2014 Jun;29(7):949-53. doi: 10.1002/mds.25831.

Depletion of canonical Wnt signaling components has a neuroprotective effect on midbrain dopaminergic neurons in an MPTP-induced mouse model of Parkinson's disease.

Dai TL, Zhang C, Peng F, Niu XY, Hu L, Zhang Q, Huang Y, Chen L, Zhang L, Zhu W, Ding YQ, Song NN, Liao M.

Exp Ther Med. 2014 Aug;8(2):384-390.

Chronic stress and Parkinson's disease.

Hou G, Tian R, Li J, Yuan TF.

CNS Neurosci Ther. 2014 Jan;20(1):1-2. doi: 10.1111/cns.12209. No abstract available.

Saccadic eye movements in Parkinson's disease.

Srivastava A, Sharma R, Sood SK, Shukla G, Goyal V, Behari M.

Indian J Ophthalmol. 2014 May;62(5):538-44. doi: 10.4103/0301-4738.133482. Review.

Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.

Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, deToledo-Morrell L, Goetz CG.

Brain. 2014 Mar;137(Pt 3):849-59. doi: 10.1093/brain/awt360.

Association between 5-HTTLPR polymorphism and Parkinson's disease: a meta analysis.

Gao L, Gao H.

Mol Biol Rep. 2014 Sep;41(9):6071-82. doi: 10.1007/s11033-014-3484-z.

The reconstructive management of hardware-related scalp erosion in deep brain stimulation for Parkinson disease.

Gómez R, Hontanilla B.

Ann Plast Surg. 2014 Sep;73(3):291-4. doi: 10.1097/SAP.0b013e318276da63.

Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of Parkinson's disease treated with L-DOPA.

Dominguez-Meijide A, Villar-Cheda B, Garrido-Gil P, Sierrra-Paredes G, Guerra MJ, Labandeira-Garcia JL.

Neuropharmacology. 2014 Jan;76 Pt A:156-68. doi: 10.1016/j.neuropharm.2013.07.016.

Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function.

Contu VR, Kotake Y, Toyama T, Okuda K, Miyara M, Sakamoto S, Samizo S, Sanoh S, Kumagai Y, Ohta S.

J Neurochem. 2014 Sep;130(6):826-38. doi: 10.1111/jnc.12762.

Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Chou VP, Ko N, Holman TR, Manning-Boğ AB.

J Vis Exp. 2014 Jan 7;(83):e50960. doi: 10.3791/50960.